4D Molecular Therapeutics Inc (NASDAQ: FDMT) on Friday, soared 0.95% from the previous trading day, before settling in for the closing price of $8.45. Within the past 52 weeks, FDMT’s price has moved between $8.37 and $36.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 111.29% annually for the last half of the decade. The company achieved an average annual earnings per share of -4.96%. With a float of $43.74 million, this company’s outstanding shares have now reached $51.97 million.
In an organization with 147 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 56.23%, operating margin of -649.02%, and the pretax margin is -543.54%.
4D Molecular Therapeutics Inc (FDMT) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of 4D Molecular Therapeutics Inc is 15.84%, while institutional ownership is 105.44%. The most recent insider transaction that took place on Sep 16 ’24, was worth 8,165. In this transaction Chief Legal Officer of this company sold 500 shares at a rate of $16.33, taking the stock ownership to the 6,781 shares. Before that another transaction happened on Aug 19 ’24, when Company’s Chief Legal Officer sold 500 for $15.00, making the entire transaction worth $7,500. This insider now owns 6,781 shares in total.
4D Molecular Therapeutics Inc (FDMT) Performance Highlights and Predictions
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.24 earnings per share (EPS) for the period topping the consensus outlook (set at -0.59) by 0.35. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -4.96% per share during the next fiscal year.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
4D Molecular Therapeutics Inc (FDMT) is currently performing well based on its current performance indicators. A quick ratio of 28.48 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 20.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -3.17 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Let’s dig in a bit further. During the last 5-days, its volume was 0.54 million. That was inferior than the volume of 0.9 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 8.45%. Additionally, its Average True Range was 0.64.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 0.78%, which indicates a significant decrease from 6.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.23% in the past 14 days, which was lower than the 101.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.02, while its 200-day Moving Average is $21.44. However, in the short run, 4D Molecular Therapeutics Inc’s stock first resistance to watch stands at $8.65. Second resistance stands at $8.77. The third major resistance level sits at $8.87. If the price goes on to break the first support level at $8.43, it is likely to go to the next support level at $8.33. Assuming the price breaks the second support level, the third support level stands at $8.21.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
Market capitalization of the company is 443.30 million based on 51,703K outstanding shares. Right now, sales total 20,720 K and income totals -100,840 K. The company made 10 K in profit during its latest quarter, and -34,950 K in sales during its previous quarter.
